Clinical trial
A Single-arm Phase 2 Study of Sugemalimab and Chemotherapy as Induction Therapy in Unresectable and Stage III Non-small Cell Lung Cancer (NSCLC)
NCT05940532 is registered in ClinicalTrials.gov with Hunan Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm Phase 2 Study of Sugemalimab and Chemotherapy as Induction Therapy in Unresectable and Stage III Non-small Cell Lung Cancer (NSCLC)
- Lead sponsor
- Hunan Cancer Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 14, 2023
- Completion date
- December 31, 2026
- Enrollment
- 41 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.